Breast Cancer Res Treat. 2009 Sep;117(2):319-24. Epub 2009 Jan 10.

Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century.

Pagani O, Price KN, Gelber RD, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thürlimann B, Collins J, Fey MF, Coates AS, Goldhirsch A; International Breast Cancer Study Group (IBCSG).

Source

Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland. olivia.pagani@ibcsg.org

Abstract

The current therapeutic strategy in breast cancer is to identify a target, such as estrogen receptor (ER) status, for tailoring treatments. We investigated the patterns of recurrence with respect to ER status for patients treated in two randomized trials with 25 years' median follow-up. In the ER-negative subpopulations most breast cancer events occurred within the first 5-7 years after randomization, while in the ER-positive subpopulations breast cancer events were spread through 10 years. In the ER-positive subpopulation, 1 year endocrine treatment alone significantly prolonged disease-free survival (DFS) with no additional benefit observed by adding 1 year of chemotherapy. In the small ER-negative subpopulation chemo-endocrine therapy had a significantly better DFS than endocrine alone or no treatment. Despite small numbers of patients, "old-fashioned" treatments, and competing causes of treatment failure, the value of ER status as a target for response to adjuvant treatment is evident through prolonged follow-up.

PMID:: 19137426; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Other Literature Sources

COS Scholar Universe

Medical

Breast Cancer - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. [J Clin Oncol. 2003]
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. J Clin Oncol. 2003 May 15; 21(10):1973-9.
Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. [Breast Cancer Res Treat. 2009]
Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer.
Dignam JJ, Dukic V, Anderson SJ, Mamounas EP, Wickerham DL, Wolmark N. Breast Cancer Res Treat. 2009 Aug; 116(3):595-602. Epub 2008 Oct 2.
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. [J Clin Oncol. 2008]
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, et al. J Clin Oncol. 2008 Mar 20; 26(9):1404-10.
Review LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. [Cochrane Database Syst Rev. 2008]
Review LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R, Hamilton A, Beith J. Cochrane Database Syst Rev. 2008 Oct 8; (4):CD004562. Epub 2008 Oct 8.
Review WITHDRAWN: Tamoxifen for early breast cancer. [Cochrane Database Syst Rev. 2008]
Review WITHDRAWN: Tamoxifen for early breast cancer.
Clarke MJ. Cochrane Database Syst Rev. 2008 Oct 8; (4):CD000486. Epub 2008 Oct 8.

See reviews... See all...

Cited by 3 PubMed Central articles

Cancer, fertility preservation, and future pregnancy: a comprehensive review. [Obstet Gynecol Int. 2012]
Cancer, fertility preservation, and future pregnancy: a comprehensive review.
Matthews ML, Hurst BS, Marshburn PB, Usadi RS, Papadakis MA, Sarantou T. Obstet Gynecol Int. 2012; 2012:953937. Epub 2012 Mar 18.
The secretory small GTPase Rab27B as a marker for breast cancer progression. [Oncotarget. 2010]
The secretory small GTPase Rab27B as a marker for breast cancer progression.
Hendrix A, Braems G, Bracke M, Seabra M, Gahl W, De Wever O, Westbroek W. Oncotarget. 2010 Aug; 1(4):304-8.
Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis. [J Natl Cancer Inst. 2010]
Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis.
Hendrix A, Maynard D, Pauwels P, Braems G, Denys H, Van den Broecke R, Lambert J, Van Belle S, Cocquyt V, Gespach C, et al. J Natl Cancer Inst. 2010 Jun 16; 102(12):866-80. Epub 2010 May 18.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Patterns of recurrence of early breast cancer according to estrogen receptor sta...
Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century.
Breast Cancer Res Treat. 2009 Sep ;117(2):319-24. Epub 2009 Jan 10 .

PubMed
Expression of multidrug resistance-1 protein correlates with disease activity ra...
Expression of multidrug resistance-1 protein correlates with disease activity rather than the refractoriness to methotrexate therapy in rheumatoid arthritis.
Clin Rheumatol. 2009 Apr ;28(4):427-33. Epub 2009 Jan 10 .

PubMed
[Computed tomography of pancreatic tumors].
[Computed tomography of pancreatic tumors].
Radiologe. 2009 Feb ;49(2):107-23.

PubMed
Recovery of ionizing-radiation damage after high doses of gamma ray in the hyper...
Recovery of ionizing-radiation damage after high doses of gamma ray in the hyperthermophilic archaeon Thermococcus gammatolerans.
Extremophiles. 2009 Mar ;13(2):333-43. Epub 2009 Jan 11 .

PubMed
Serotonin transporter gene polymorphism (5-HTTLPR), environmental conditions, an...
Serotonin transporter gene polymorphism (5-HTTLPR), environmental conditions, and developing negative emotionality and fear in early childhood.
J Neural Transm. 2009 Apr ;116(4):503-12. Epub 2009 Jan 10 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century.

Source

Abstract

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Cited by 3 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information